{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-310408","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.449134+00:00","generated_at":"2026-06-28T17:04:07.970249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M","bullets":["Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.","GAAP EPS of $0.58, Adjusted EPS of $0.78; GAAP operating margin rose to 25.4%.","FY 2021 revenue guidance raised to $655-665M (prior $625-645M); adjusted EPS guidance raised to $2.86-$2.91.","Completed acquisition of affinity ligands innovator Avitide Inc. during the quarter.","COVID programs contributed 27% of Q3 revenue; base business grew 49% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-310408","json":"https://secwatch.observer/filing/0001193125-21-310408.json","markdown":"https://secwatch.observer/filing/0001193125-21-310408.md","text":"https://secwatch.observer/filing/0001193125-21-310408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312521310408/0001193125-21-310408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312521310408/d83679d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:04:07.970249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}